

# Charles L Cowey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1723897/publications.pdf>

Version: 2024-02-01

12  
papers

13,070  
citations

1163117

8  
h-index

1372567

10  
g-index

12  
all docs

12  
docs citations

12  
times ranked

17507  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma. <i>Future Oncology</i> , 2022, , .	2.4	0
2	383â€¦Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695. , 2021, 9, A417-A417.		2
3	An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAFâ€ˆmutant advanced melanoma treated with firstâ€ˆline antiâ€ˆPDâ€ˆ1 monotherapies or BRAF/MEK inhibitors in a communityâ€ˆbased oncology setting. <i>Cancer Medicine</i> , 2020, 9, 7863-7878.	2.8	4
4	Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. <i>Cancer Medicine</i> , 2020, 9, 7381-7387.	2.8	39
5	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	27.0	2,484
6	A phase 2 study of glembatumumab vedotin, an antibodyâ€ˆdrug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019, 125, 1113-1123.	4.1	45
7	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	1.0	30
8	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	27.0	3,589
9	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	1.9	15
10	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
11	BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. <i>Lung Cancer</i> , 2014, 85, 326-330.	2.0	82
12	Molecularly targeted agents for renal cell carcinoma: the next generation. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 357-60, 361-4.	0.3	7